


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1. (Original) A compound according to general formula 1, or a pharmaceutically acceptable salt thereof




1

wherein:


- G¹ is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;




2




3




4



5




6



7

- A<sup>1</sup> is selected from CH<sub>2</sub>, CH(OH), NH, N-alkyl, O and S;
- A<sup>2</sup> is selected from CH<sub>2</sub>, CH(OH), C(=O) and NH;
- A<sup>3</sup> is selected from S, NH, N-alkyl, -CH=CH- and -CH=N-;
- A<sup>4</sup> and A<sup>5</sup> are each selected from CH and N;
- A<sup>6</sup> is selected from CH<sub>2</sub>, NH, N-alkyl and O;
- A<sup>7</sup> and A<sup>11</sup> are selected from C and N;
- A<sup>8</sup> and A<sup>9</sup> are selected from CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> and S;
- A<sup>10</sup> is selected from -CH=CH-, CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> and S;
- A<sup>12</sup> and A<sup>13</sup> are selected from N and C;
- A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> are selected from NH, N-CH<sub>3</sub>, S, N and CH;
- X<sup>1</sup> is selected from O and NH;
- R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each selected from H, alkyl, O-alkyl, F, Cl and Br;
- R<sup>4</sup> is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, -(CH<sub>2</sub>)<sub>e</sub>R<sup>8</sup>, -CH<sub>2</sub>-CH=CH-CH<sub>2</sub>-R<sup>8</sup>, -CH<sub>2</sub>-C≡C-

CH<sub>2</sub>-R<sup>8</sup>, -(CH<sub>2</sub>)<sub>g</sub>-CH(OH)-(CH<sub>2</sub>)<sub>h</sub>-R<sup>8</sup>, -(CH<sub>2</sub>)<sub>i</sub>-O-(CH<sub>2</sub>)<sub>j</sub>-R<sup>8</sup> and  R<sup>8</sup> ;

- R<sup>5</sup> and R<sup>6</sup> are independently selected from alkyl, Ar and -(CH<sub>2</sub>)<sub>f</sub>-Ar;
- R<sup>7</sup> is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, NH-acyl, N(alkyl)-acyl, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;
- R<sup>8</sup> is selected from H, alkyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, OH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)-acyl, N<sub>3</sub>, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;
- Ar is selected from optionally substituted thienyl and optionally substituted phenyl;

- a is 1 or 2, b is 1, 2 or 3; c is 1 or 2, d is 1, 2 or 3; e is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2;

provided that:

- not more than one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S;
- A<sup>7</sup> and A<sup>11</sup> are not both simultaneously N;
- neither A<sup>7</sup> nor A<sup>11</sup> is N if one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S;
- if A<sup>10</sup> is not —CH=CH— then one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S or one of A<sup>7</sup> and A<sup>11</sup> is N;
- not more than one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N—CH<sub>3</sub> or S;
- A<sup>12</sup> and A<sup>13</sup> are not both simultaneously N;
- if one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N—CH<sub>3</sub> or S then A<sup>12</sup> and A<sup>13</sup> are both C; and
- one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N—CH<sub>3</sub> or S or one of A<sup>12</sup> and A<sup>13</sup> is N,

wherein said compound is selected from the group consisting of:

- 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; and
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide.

2. (Original) A pharmaceutical composition comprising a compound according to claim 1 as an active agent.


3. (Original) A pharmaceutical composition according to Claim 2 formulated as a tablet or capsule for oral administration.

4. (Currently Amended) A pharmaceutical composition according to Claim 2 ~~or 3~~ for treatment of primary dysmenorrhoea.

5. (Currently Amended) A pharmaceutical composition according to Claim 2 ~~or 3~~ for treatment of male erectile dysfunction.


6. (Currently Amended) A pharmaceutical composition according to Claim 2 ~~or 3~~ for treatment of pre-term labour, hypertension, Raynaud's disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis or congestive heart failure.

7. (Original) The use of a compound according to general formula 1, or a pharmaceutically acceptable salt thereof




wherein:

- G<sup>1</sup> is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;



5

6



7

- A<sup>1</sup> is selected from CH<sub>2</sub>, CH(OH), NH, N-alkyl, O and S;
- A<sup>2</sup> is selected from CH<sub>2</sub>, CH(OH), C(=O) and NH;
- A<sup>3</sup> is selected from S, NH, N-alkyl, -CH=CH- and -CH=N-;
- A<sup>4</sup> and A<sup>5</sup> are each selected from CH and N;
- A<sup>6</sup> is selected from CH<sub>2</sub>, NH, N-alkyl and O;
- A<sup>7</sup> and A<sup>11</sup> are selected from C and N;
- A<sup>8</sup> and A<sup>9</sup> are selected from CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> and S;
- A<sup>10</sup> is selected from -CH=CH-, CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> and S;
- A<sup>12</sup> and A<sup>13</sup> are selected from N and C;
- A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> are selected from NH, N-CH<sub>3</sub>, S, N and CH;
- X<sup>1</sup> is selected from O and NH;
- R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each selected from H, alkyl, O-alkyl, F, Cl and Br;
- R<sup>4</sup> is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, -(CH<sub>2</sub>)<sub>e</sub>R<sup>8</sup>, -CH<sub>2</sub>-CH=CH-CH<sub>2</sub>-R<sup>8</sup>, -CH<sub>2</sub>-C≡C-

CH<sub>2</sub>-R<sup>8</sup>, -(CH<sub>2</sub>)<sub>g</sub>-CH(OH)-(CH<sub>2</sub>)<sub>h</sub>-R<sup>8</sup>, -(CH<sub>2</sub>)<sub>i</sub>-O-(CH<sub>2</sub>)<sub>j</sub>-R<sup>8</sup> and  $\text{CH}_2-\triangle-\text{R}^8$  ;

- R<sup>5</sup> and R<sup>6</sup> are independently selected from alkyl, Ar and -(CH<sub>2</sub>)<sub>f</sub>-Ar;
- R<sup>7</sup> is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, NH-acyl, N(alkyl)-acyl, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;
- R<sup>8</sup> is selected from H, alkyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, OH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl,

NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)-acyl, N<sub>3</sub>, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;

- Ar is selected from optionally substituted thienyl and optionally substituted phenyl;

- a is 1 or 2, b is 1, 2 or 3; c is 1 or 2, d is 1, 2 or 3; e is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2;

provided that:

- not more than one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S;

- A<sup>7</sup> and A<sup>11</sup> are not both simultaneously N;

- neither A<sup>7</sup> nor A<sup>11</sup> is N if one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S;

- if A<sup>10</sup> is not -CH=CH- then one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S or one of A<sup>7</sup> and A<sup>11</sup> is N;

- not more than one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N-CH<sub>3</sub> or S;


- A<sup>12</sup> and A<sup>13</sup> are not both simultaneously N;

- if one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N-CH<sub>3</sub> or S then A<sup>12</sup> and A<sup>13</sup> are both C; and

- one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N-CH<sub>3</sub> or S or one of A<sup>12</sup> and A<sup>13</sup> is N,

for the manufacture of a pharmaceutical composition for treatment of primary dysmenorrhoea.


8. (Original) The use of a compound according to general formula 1, or a pharmaceutically acceptable salt thereof



1

wherein:


- G<sup>1</sup> is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;




2

3


4



5



6



7

- A<sup>1</sup> is selected from CH<sub>2</sub>, CH(OH), NH, N-alkyl, O and S;
- A<sup>2</sup> is selected from CH<sub>2</sub>, CH(OH), C(=O) and NH;
- A<sup>3</sup> is selected from S, NH, N-alkyl, -CH=CH- and -CH=N-;
- A<sup>4</sup> and A<sup>5</sup> are each selected from CH and N;
- A<sup>6</sup> is selected from CH<sub>2</sub>, NH, N-alkyl and O;
- A<sup>7</sup> and A<sup>11</sup> are selected from C and N;
- A<sup>8</sup> and A<sup>9</sup> are selected from CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> and S;
- A<sup>10</sup> is selected from -CH=CH-, CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> and S;
- A<sup>12</sup> and A<sup>13</sup> are selected from N and C;
- A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> are selected from NH, N-CH<sub>3</sub>, S, N and CH;
- X<sup>1</sup> is selected from O and NH;
- R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each selected from H, alkyl, O-alkyl, F, Cl and Br;
- R<sup>4</sup> is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, -(CH<sub>2</sub>)<sub>e</sub>R<sup>8</sup>, -CH<sub>2</sub>-CH=CH-CH<sub>2</sub>-R<sup>8</sup>, -CH<sub>2</sub>-C≡C-CH<sub>2</sub>-R<sup>8</sup>, -(CH<sub>2</sub>)<sub>9</sub>-CH(OH)-(CH<sub>2</sub>)<sub>h</sub>-R<sup>8</sup>, -(CH<sub>2</sub>)<sub>i</sub>-O-(CH<sub>2</sub>)<sub>j</sub>-R<sup>8</sup> and  $\text{CH}_2\text{---}\triangle\text{---R}^8$  ;
- R<sup>5</sup> and R<sup>6</sup> are independently selected from alkyl, Ar and -(CH<sub>2</sub>)<sub>f</sub>-Ar;



- R<sup>7</sup> is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, NH-acyl, N(alkyl)-acyl, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;
  - R<sup>8</sup> is selected from H, alkyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, OH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)-acyl, N<sub>3</sub>, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;
  - Ar is selected from optionally substituted thienyl and optionally substituted phenyl;
  - a is 1 or 2, b is 1, 2 or 3; c is 1 or 2, d is 1, 2 or 3; e is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2;
- provided that:
- not more than one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S;
  - A<sup>7</sup> and A<sup>11</sup> are not both simultaneously N;
  - neither A<sup>7</sup> nor A<sup>11</sup> is N if one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S;
  - if A<sup>10</sup> is not -CH=CH- then one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S or one of A<sup>7</sup> and A<sup>11</sup> is N;
  - not more than one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N-CH<sub>3</sub> or S;
  - A<sup>12</sup> and A<sup>13</sup> are not both simultaneously N;
  - if one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N-CH<sub>3</sub> or S then A<sup>12</sup> and A<sup>13</sup> are both C; and
  - one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N-CH<sub>3</sub> or S or one of A<sup>12</sup> and A<sup>13</sup> is N,
- for the manufacture of a pharmaceutical composition for treatment of pre-term labour, hypertension, Raynaud's disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis or congestive heart failure.

9. (Currently Amended) The use according to Claim 7 ~~or 8~~, wherein at least one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is H and at least one is not H.

10. (Currently Amended) The use according to ~~any one of Claims 7—9~~ Claim 7, wherein one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H.

11. (Currently Amended) The use according to ~~any one of the Claims 7—10~~ Claim 7, wherein X<sup>1</sup> is NH.

12. (Currently Amended) The use according to ~~any one of the Claims 7—11~~ Claim 7, wherein a is 1 and b is 2.

13. (Currently Amended) The use according to ~~any one of the Claims 7—12~~ Claim 7, wherein G<sup>1</sup> is a group according to general formula 3.

14. (Original) The use according to Claim 13, wherein c is 2.

15. (Currently Amended) The use according to Claim 13 ~~or 14~~, wherein A<sup>1</sup> is CH<sub>2</sub> and A<sup>2</sup> is NH.

16. (Currently Amended) The use according to Claim 13 ~~or 14~~, wherein A<sup>1</sup> is NH or N-alkyl and A<sup>2</sup> is C(=O).

17. (Currently Amended) The use according to Claim 13 ~~or 14~~, wherein A<sup>3</sup> is S and A<sup>4</sup> and A<sup>5</sup> are both CH.

18. (Currently Amended) The use according to ~~any of Claims 13—17~~ Claim 13, wherein A<sup>3</sup> is —CH=CH- and A<sup>4</sup> and A<sup>5</sup> are both CH.

19. (Currently Amended) The use according to ~~any of Claims 13—17~~ Claim 13, wherein A<sup>3</sup> is —CH=N- and A<sup>4</sup> and A<sup>5</sup> are both CH.

20. (Currently Amended) The use according to ~~any of Claims 13—17~~ Claim 13, wherein A<sup>3</sup> is —CH=CH-, A<sup>4</sup> is CH and A<sup>5</sup> is N.

21. (Currently Amended) The use according to ~~any of Claims 7—12~~ Claim 7, wherein G<sup>1</sup> is a group according to general formula 6 or 7

22. (Original) The use according to Claim 21, wherein A<sup>3</sup> is S and A<sup>4</sup> and A<sup>5</sup> are both CH.

23. (Original) The use according to Claim 21, wherein A<sup>3</sup> is —CH=CH- and A<sup>4</sup> and A<sup>5</sup> are both CH.

24. (Original) The use according to Claim 21, wherein A<sup>3</sup> is —CH=N- and A<sup>4</sup> and A<sup>5</sup> are both CH.

25. (Original) The use according to Claim 21, wherein A<sup>3</sup> is —CH=CH-, A<sup>4</sup> is CH and A<sup>5</sup> is N.

26. (Currently Amended) The use according to ~~any one to Claims 7—12~~ Claim 7, wherein G<sup>1</sup> is a group according to general formula 4 or 6.

27. (Original) The use according to Claim 26, wherein A<sup>6</sup> is NH.
28. (Currently Amended) The use according to Claim 26 ~~or 27~~, wherein A<sup>8</sup> is NH or N-(CH<sub>2</sub>)<sub>d</sub>-R<sup>7</sup>.
29. (Original) The use according to Claim 28, wherein A<sup>9</sup> is N and A<sup>10</sup> is CH.
30. (Currently Amended) The use according to Claim 7 ~~or 8~~, wherein one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and X<sup>1</sup> is NH.
31. (Currently Amended) The use according to ~~any one of Claims 7 or 8~~ Claim 7, wherein one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and X<sup>1</sup> is NH, a is 1 and b is 2.
32. (Currently Amended) The use according to Claim 7 ~~or 8~~, wherein G<sup>1</sup> is a group according to general formula 6, A<sup>4</sup>, A<sup>5</sup> and A<sup>10</sup> are all CH, A<sup>6</sup> is NH, A<sup>7</sup> and A<sup>11</sup> are both C, A<sup>8</sup> is N-(CH<sub>2</sub>)<sub>d</sub>-R<sup>7</sup> and A<sup>9</sup> is N.
33. (Currently Amended) The use according to Claim 7 ~~or 8~~, wherein R<sup>1</sup> is an alkyl group, an O-alkyl group, F, Cl or Br, R<sup>2</sup> and R<sup>3</sup> are both H, X<sup>1</sup> is NH, a is 1, b is 2, G<sup>1</sup> is a group according to general formula 6, A<sup>4</sup>, A<sup>5</sup> and A<sup>10</sup> are all CH, A<sup>6</sup> is NH, A<sup>7</sup> and A<sup>11</sup> are both C, A<sup>8</sup> is N-(CH<sub>2</sub>)<sub>d</sub>-R<sup>7</sup> and A<sup>9</sup> is N.
34. (Currently Amended) The use according to Claim 7 ~~or 8~~, wherein said compound is selected from the group consisting of:
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(3-Methylsulfanyl-propyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide, and
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide.


35. (Original) The use of a compound selected from the group consisting of:

- 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide, and
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- for the manufacture of a pharmaceutical composition for treatment of male erectile dysfunction.






36. (Original) A method for treatment of a disorder selected from the group consisting of primary dysmenorrhoea, pre-term labour, hypertension, Raynaud's disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure which comprises the

administration to a person in need of such treatment of therapeutically effective amount of a compound according to general formula 1, or a pharmaceutically acceptable salt thereof




wherein:

- G¹ is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;



- A¹ is selected from CH₂, CH(OH), NH, N-alkyl, O and S;  
 - A² is selected from CH₂, CH(OH), C(=O) and NH;  
 - A³ is selected from S, NH, N-alkyl, -CH=CH- and -CH=N-;

- A<sup>4</sup> and A<sup>5</sup> are each selected from CH and N;
- A<sup>6</sup> is selected from CH<sub>2</sub>, NH, N-alkyl and O;
- A<sup>7</sup> and A<sup>11</sup> are selected from C and N;
- A<sup>8</sup> and A<sup>9</sup> are selected from CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> and S;
- A<sup>10</sup> is selected from -CH=CH-, CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> and S;
- A<sup>12</sup> and A<sup>13</sup> are selected from N and C;
- A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> are selected from NH, N-CH<sub>3</sub>, S, N and CH;
- X<sup>1</sup> is selected from O and NH;
- R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each selected from H, alkyl, O-alkyl, F, Cl and Br;
- R<sup>4</sup> is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, -(CH<sub>2</sub>)<sub>e</sub>R<sup>8</sup>, -CH<sub>2</sub>-CH=CH-CH<sub>2</sub>-R<sup>8</sup>, -CH<sub>2</sub>-C≡C-

CH<sub>2</sub>-R<sup>8</sup>, -(CH<sub>2</sub>)<sub>g</sub>-CH(OH)-(CH<sub>2</sub>)<sub>h</sub>-R<sup>8</sup>, -(CH<sub>2</sub>)<sub>i</sub>-O-(CH<sub>2</sub>)<sub>j</sub>-R<sup>8</sup> and  ;

- R<sup>5</sup> and R<sup>6</sup> are independently selected from alkyl, Ar and -(CH<sub>2</sub>)<sub>t</sub>-Ar;
- R<sup>7</sup> is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, NH-acyl, N(alkyl)-acyl, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;
- R<sup>8</sup> is selected from H, alkyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, OH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)-acyl, N<sub>3</sub>, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;
- Ar is selected from optionally substituted thienyl and optionally substituted phenyl;
- a is 1 or 2, b is 1, 2 or 3; c is 1 or 2, d is 1, 2 or 3; e is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2;

provided that:

- not more than one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S;
- A<sup>7</sup> and A<sup>11</sup> are not both simultaneously N;
- neither A<sup>7</sup> nor A<sup>11</sup> is N if one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S;
- if A<sup>10</sup> is not -CH=CH- then one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S or one of A<sup>7</sup> and A<sup>11</sup> is N;
- not more than one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N-CH<sub>3</sub> or S;
- A<sup>12</sup> and A<sup>13</sup> are not both simultaneously N;
- if one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N-CH<sub>3</sub> or S then A<sup>12</sup> and A<sup>13</sup> are both C; and



- one of A<sup>14</sup>, A<sup>15</sup> and A<sup>16</sup> is NH, N—CH<sub>3</sub> or S or one of A<sup>12</sup> and A<sup>13</sup> is N.

37. (Original) The method of Claim 36, wherein at least one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is H and at least one is not H.

38. (Original) The method of Claim 36, wherein one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H.

39. (Original) The method of Claim 36, wherein X<sup>1</sup> is NH.

40. (Original) The method of Claim 36, wherein a is 1 and b is 2.

41. (Original) The method of Claim 36, wherein G<sup>1</sup> is a group according to general formula 3.

42. (Original) The method of to Claim 41, wherein c is 2.

43. (Original) The method of Claim 41, wherein A<sup>1</sup> is CH<sub>2</sub> and A<sup>2</sup> is NH.

44. (Original) The method of Claim 41, wherein A<sup>1</sup> is NH or N-alkyl and A<sup>2</sup> is C(=O).

45. (Original) The method of Claim 41, wherein A<sup>3</sup> is S and A<sup>4</sup> and A<sup>5</sup> are both CH.

46. (Original) The method of Claim 41, wherein A<sup>3</sup> is —CH=CH- and A<sup>4</sup> and A<sup>5</sup> are both CH.

47. (Original) The method of Claim 41, wherein A<sup>3</sup> is —CH=N- and A<sup>4</sup> and A<sup>5</sup> are both CH.

48. (Original) The method of Claim 41, wherein A<sup>3</sup> is —CH=CH-, A<sup>4</sup> is CH and A<sup>5</sup> is N.

49. (Original) The method of Claim 36, wherein G<sup>1</sup> is a group according to general formula 6 or 7.

50. (Original) The method of Claim 49, wherein A<sup>3</sup> is S and A<sup>4</sup> and A<sup>5</sup> are both CH.

51. (Original) The method of Claim 49, wherein A<sup>3</sup> is —CH=CH- and A<sup>4</sup> and A<sup>5</sup> are both CH.

52. (Original) The method of Claim 49, wherein A<sup>3</sup> is —CH=N- and A<sup>4</sup> and A<sup>5</sup> are both CH.

53. (Original) The method of Claim 49, wherein A<sup>3</sup> is —CH=CH—, A<sup>4</sup> is CH and A<sup>5</sup> is N.
54. (Original) The method of Claim 36, wherein G<sup>1</sup> is a group according to general formula 4 or 6.
55. (Original) The method of Claim 54, wherein A<sup>6</sup> is NH.
56. (Original) The method of Claim 54, wherein A<sup>8</sup> is NH or N-(CH<sub>2</sub>)<sub>d</sub>-R<sup>7</sup>.
57. (Original) The method of Claim 56, wherein A<sup>9</sup> is N and A<sup>10</sup> is CH.
58. (Original) The method of Claim 36, wherein one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and X<sup>1</sup> is NH.
59. (Original) The method of Claim 36, wherein one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and X<sup>1</sup> is NH, a is 1 and b is 2.
60. (Original) The method of Claim 36, wherein G<sup>1</sup> is a group according to general formula 6, A<sup>4</sup>, A<sup>5</sup> and A<sup>10</sup> are all CH, A<sup>6</sup> is NH, A<sup>7</sup> and A<sup>11</sup> are both C, A<sup>8</sup> is N-(CH<sub>2</sub>)<sub>d</sub>-R<sup>7</sup> and A<sup>9</sup> is N.
61. (Original) The method of Claim 36, wherein R<sup>1</sup> is an alkyl group, an O-alkyl group, F, Cl or Br, R<sup>2</sup> and R<sup>3</sup> are both H, X<sup>1</sup> is NH, a is 1, b is 2, G<sup>1</sup> is a group according to general formula 6, A<sup>4</sup>, A<sup>5</sup> and A<sup>10</sup> are all CH, A<sup>6</sup> is NH, A<sup>7</sup> and A<sup>11</sup> are both C, A<sup>8</sup> is N-(CH<sub>2</sub>)<sub>d</sub>-R<sup>7</sup> and A<sup>9</sup> is N.
62. (Original) The method of Claim 36, wherein said compound is selected from the group consisting of:
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(3-Methylsulfanyl-propyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide, and
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide.

63. (Original) A method for treatment of male erectile dysfunction which comprises the administration to a person in need of such treatment of therapeutically effective amount of a compound selected from the group consisting of:

- 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
  - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; and
- pharmaceutically acceptable salts of the above mentioned compounds.